These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 34496081)

  • 41. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.
    Băjenaru O; Ene A; Popescu BO; Szász JA; Sabău M; Mureşan DF; Perju-Dumbrava L; Popescu CD; Constantinescu A; Buraga I; Simu M
    J Neural Transm (Vienna); 2016 Apr; 123(4):407-14. PubMed ID: 26699635
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
    Wirdefeldt K; Odin P; Nyholm D
    CNS Drugs; 2016 May; 30(5):381-404. PubMed ID: 27138916
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].
    Toth A; Nagy H; Wacha J; Bereczki D; Takáts A
    Neuropsychopharmacol Hung; 2015 Dec; 17(4):191-6. PubMed ID: 26727723
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
    Block G; Liss C; Reines S; Irr J; Nibbelink D
    Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry.
    Buongiorno M; Antonelli F; Cámara A; Puente V; de Fabregues-Nebot O; Hernandez-Vara J; Calopa M; Pascual-Sedano B; Campolongo A; Valldeoriola F; Tolosa E; Kulisevsky J; Martí MJ
    Parkinsonism Relat Disord; 2015 Aug; 21(8):871-6. PubMed ID: 26003410
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
    Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV
    Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: a long-term prospective assessment.
    Merola A; Romagnolo A; Zibetti M; Bernardini A; Cocito D; Lopiano L
    Eur J Neurol; 2016 Mar; 23(3):501-9. PubMed ID: 26498913
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.
    Udd M; Lyytinen J; Eerola-Rautio J; Kenttämies A; Lindström O; Kylänpää L; Pekkonen E
    Brain Behav; 2017 Jul; 7(7):e00737. PubMed ID: 28729942
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience.
    Zibetti M; Merola A; Artusi CA; Rizzi L; Angrisano S; Reggio D; De Angelis C; Rizzone M; Lopiano L
    Eur J Neurol; 2014 Feb; 21(2):312-8. PubMed ID: 24313838
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.
    Olanow CW; Kieburtz K; Odin P; Espay AJ; Standaert DG; Fernandez HH; Vanagunas A; Othman AA; Widnell KL; Robieson WZ; Pritchett Y; Chatamra K; Benesh J; Lenz RA; Antonini A;
    Lancet Neurol; 2014 Feb; 13(2):141-9. PubMed ID: 24361112
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The relationship between the distinct ratios of benserazide and carbidopa to levodopa and motor complications in Parkinson's disease: A retrospective cohort study.
    Baba Y; Futamura A; Kinno R; Nomoto S; Takahashi S; Yasumoto T; Osakabe Y; Shoji D; Nabeshima Y
    J Neurol Sci; 2022 Jun; 437():120263. PubMed ID: 35462236
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
    Eggert K; Skogar O; Amar K; Luotonen L; Kuoppamäki M; Leinonen M; Nissinen H; Oertel W
    J Neural Transm (Vienna); 2010 Mar; 117(3):333-42. PubMed ID: 20013007
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Treatment for advanced Parkinson's disease with intestinal levodopa/carbidopa gel: review of efficacy and safety].
    Timofeeva AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):145-51. PubMed ID: 25629138
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Levodopa/carbidopa intestinal gel for pain related to levodopa-induced motor complications in Parkinson's disease.
    Rinaldi D; De Carolis L; Ceriello F; Bianchini E; Pontieri FE
    Neurol Sci; 2022 Jul; 43(7):4571-4572. PubMed ID: 35411502
    [No Abstract]   [Full Text] [Related]  

  • 55. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum.
    Rosebraugh M; Stodtmann S; Liu W; Facheris MF
    Parkinsonism Relat Disord; 2022 Apr; 97():68-72. PubMed ID: 35339102
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson's disease: results of the Italian GLORIA patient population.
    Antonini A; Marano P; Gusmaroli G; Modugno N; Pacchetti C; Sensi M; Melzi G; Bergmann L; Zibetti M; Lopiano L
    Neurol Sci; 2020 Oct; 41(10):2929-2937. PubMed ID: 32342325
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-Duration Response to Levodopa, Motor Learning, and Neuroplasticity in Early Parkinson's Disease.
    Sciacca G; Mostile G; Disilvestro I; Donzuso G; Nicoletti A; Zappia M
    Mov Disord; 2023 Apr; 38(4):626-635. PubMed ID: 36840442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: Management inclinical practice.
    Melgari JM; Salomone G; di Biase L; Marano M; Scrascia F; Di Lazzaro V
    Parkinsonism Relat Disord; 2015 Mar; 21(3):327-8. PubMed ID: 25595317
    [No Abstract]   [Full Text] [Related]  

  • 60. Central conduction abnormalities in patients receiving levodopa-carbidopa intestinal gel infusion.
    Bove F; Luigetti M; Gallicchio L; Recchia V; Petruzzellis A; Di Iorio R; Tamma F; Fasano A
    Neurol Sci; 2017 Oct; 38(10):1869-1872. PubMed ID: 28642996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.